IL23A encodes the p19 subunit of interleukin-23 (IL-23), a pro-inflammatory cytokine released by antigen-presenting cells including dendritic cells and macrophages. IL-23 associates with IL-12B to form a functional heterodimer that binds a receptor complex composed of IL12RB1 and IL23R, triggering JAK2 and TYK2 phosphorylation and subsequent STAT3 and STAT4 activation. This signaling promotes NF-κB and p38 MAPK pathway activation, driving production of IL-17 and other pro-inflammatory mediators. IL-23 expands T-helper 17 cells and supports intracellular bacterial clearance, roles central to both protective immunity and chr12 inflammation. IL-23 dysregulation underlies multiple inflammatory diseases, including psoriasis, inflammatory bowel disease, ankylosing spondylitis, and asthma. Critically, targeted IL-23 blockade has become a major therapeutic strategy: monoclonal antibodies against the p19 subunit (risankizumab, mirikizumab, guselkumab, and others) demonstrate superior efficacy in moderate-to-severe psoriasis, with over 70% of patients achieving near-complete skin clearance 1. In ulcerative colitis, mirikizumab induced clinical response in 59.7% of patients at the 200 mg dose compared to 20.6% for placebo 2. These p19-targeting agents show durable responses with dosing intervals extending to 3 months and safety profiles comparable to placebo 1. IL-23 p19 inhibitors also demonstrate efficacy in Darier disease skin inflammation 3, establishing IL-23 as a converging pathogenic mechanism across diverse inflammatory conditions.